Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific has received approval from FDA to market Taxus Liberte Atom paclitaxel eluting coronary stent system, a drug eluting stent (DES) designed for treating small coronary vessels, as small as 2.25mm in diameter. The Taxus Liberte Atom joins the Taxus Express Atom stent as the only next-generation drug eluting stent DES approved for small vessel use in the US.
Subscribe to our email newsletter
Taxus Express Atom Stent offers an alternative treatment choice for patients with small vessels who will now have the additional option of the Taxus Liberte Atom Stent.
Mark Turco, Director of the Center for Cardiac and Vascular Research at Washington Adventist Hospital, said: “The rapid adoption of the Taxus Express Atom Stent has confirmed the need for this type of stenting option in the treatment of small-vessel coronary artery disease,”
“The Taxus Liberté Atom Stent provides clear design and deliverability advantages. Additionally, in the Taxus Atlas Small Vessel clinical trial, the Taxus Liberte Atom Stent yielded a two-year target lesion revascularization rate that was 60% less than the Taxus Express Atom Stent. I am pleased to be able to offer this option to my patients, he added.